| HOME >> BIOLOGY >> TECHNOLOGY |
PARIS, November 8 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, has completed a prototype of the first blood-based Alzheimer's disease test. The company expects to have this test certified and to provide it as a service in its GLP (Good Laboratory Practices) compliant laboratories to the pharmaceutical industry as early as 2009.
This initial ExonHit test aims to identify patients suffering from Alzheimer's disease from a simple blood sample. Further developments are underway to assess if it is feasible to identify, at an early stage, patients suffering from MCI (Mild Cognitive Impairment) who are at risk to develop Alzheimer-type dementia.
The performances of this test have been improved since March 2007, where it now detects the presence of Alzheimer's disease in patients presenting with cognitive disorders, as determined by a MMSE (Mini Mental State Examination) score < 20 and a GDS (Global Deterioration Scale) score greater than or equal to 4. Importantly, the test has a specificity and a sensitivity of greater than 95% for AD, calculated from a sample of 174 patients. As well as providing doctors with a simple measure of the illness, the test's performances are by far superior to current standards.
This test is based on hybridising nucleic acids (RNA), isolated from a blood sample, on a custom microarray produced by Affymetrix which contains sequences identified using ExonHit's patented human genome screening technology. The blood test can distinguish patients suffering from Alzheimer's disease from those suffering from bipolar disorders, schizophrenia or depression. The identified sequences (or "signature") were found to be typical in the blood of patients suffering from Alzheimer's disease can be grouped and are representative of alterations of well known metabolic functions.
"Considering our biological signature's properties, we are confident
that the test will also be able to screen ou
'/>"/>
| SOURCE ExonHit Therapeutics SA Copyright©2007 PR Newswire. All rights reserved |